Helping guide the success of your product development
In drug development, a proper clinical development strategy, implemented at an early stage of product development, helps to guide the success (and cost-effectiveness) of the product development. To understand the kinetics of a drug in terms of absorption, distribution, metabolism and elimination (ADME), pharmacokinetic (PK) studies are performed. In addition, often the pharmacodynamics (PD), ie. the biochemical and physiologic effects of the drug, are monitored. To analyse PK and/or PD data, non-compartmental analysis (NCA) and model-based analysis (modelling & simulation) are used.
For more than 20 years, (interim) noncompartmental PK and PD analyses have been performed within Venn Life Sciences for many pharmaceutical companies for all types of Phase 1 studies including first-in-man, ADME studies, drug-drug interaction studies, bioequivalence and bioavailability studies, studies in special populations and other PK studies during Phase 2/3.